Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.2826
-0.0252-8.19%
Post-market: 0.28710.0045+1.59%19:59 EDT
Volume:2.03M
Turnover:595.39K
Market Cap:12.54M
PE:-0.17
High:0.3140
Open:0.3077
Low:0.2793
Close:0.3078
52wk High:5.14
52wk Low:0.1980
Shares:44.38M
Float Shares:41.42M
Volume Ratio:0.28
T/O Rate:4.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6559
EPS(LYR):-1.8303
ROE:-166.46%
ROA:-83.21%
PB:0.51
PE(LYR):-0.15

Loading ...

VistaGen Says Phase 2 Repeat-Dose Fasedienol Study in Social Anxiety Disorder Shows Favorable Safety, Efficacy Signals

Reuters
·
Aug 06

Vistagen Therapeutics - Repeat Dose Fasedienol Demonstrates Favorable Safety and Tolerability Similar to Single Dose

THOMSON REUTERS
·
Aug 06

Vistagen Therapeutics - Nominally Statistically Significant Improvement in Very Severe Social Anxiety Disorder Patients

THOMSON REUTERS
·
Aug 06

Vistagen Therapeutics - Efficacy Signals Observed Across Primary and Secondary Endpoints for Fasedienol

THOMSON REUTERS
·
Aug 06

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Aug 06

VistaGen Gets NASDAQ Extension to Regain $1 Minimum Bid Price Compliance

Reuters
·
Aug 06

Top Premarket Gainers

MT Newswires Live
·
Aug 04

SRX Global acquires stake in Vistagen

TIPRANKS
·
Aug 04

SRX Global Acquires Stake in Vistagen Therapeutics

Reuters
·
Aug 04

Srx Global Acquires Stake in Vistagen Therapeutics (Nasdaq: Vtgn)

THOMSON REUTERS
·
Aug 04

Vistagen Therapeutics Inc Expected to Post a Loss of 36 Cents a Share - Earnings Preview

Reuters
·
Aug 04

VistaGen Announces Annual Shareholder Meeting

Reuters
·
Aug 01

VistaGen Files Form 3 as Director Douglas J. Williamson Reports no Beneficial Ownership

Reuters
·
Jul 31

VistaGen Names Douglas J. Williamson to Board of Directors

Reuters
·
Jul 31

Vistagen Appoints Douglas J. Williamson to Its Board of Directors

THOMSON REUTERS
·
Jul 31

Vistagen Announces Topline and Post-hoc Data from Palisade-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Reuters
·
Jul 06

Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)

TIPRANKS
·
Jul 06

VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Jul 01

Vistagen Tumbles as Social Anxiety Drug Misses Main Goal in Late-stage Trial

Reuters
·
Jun 30

Vistagen Therapeutics Says Fasedienol Didn't Meet Primary Endpoint in Study

Dow Jones
·
Jun 30